hˌaɪpoʊɡlaɪsˈiːmiə ɪlˈɛvən twˈɛlv pɚsˈɛnt wˌaɪl ɪt wʌz ʃˈoʊn tə hæv ðə sˈeɪm ˈɛfɪkəsi æz ɡlˈaɪmpɪɹˌɪd, wˈʌn ʌvðə nˈuːɚ sˌʌlfənˌɪlʊɹɹˈiəz, ðə jˌʊɹɹəpˈiən ɡˈaɪd stˈʌdi hɐz ʃˈoʊn ðˌɐɾɪt hɐz ɐpɹˈɑːksɪmətli fˈɪfti pɚsˈɛnt lˈɛs hˌaɪpoʊɡlaɪsˈiːmɪk kənfˈɜːmd ˈɛpɪsˌoʊdz ɪn kəmpˈæɹɪsən wɪð ɡlˈaɪmpɪɹˌɪd.
Hypoglycemia (11 - 12%) - while it was shown to have the same efficacy as glimepiride, one of the newer sulfonylureas, the European GUIDE study has shown that it has approximately 50% less hypoglycemic confirmed episodes in comparison with glimepiride.